Mirum Pharmaceuticals Inc. Common Stock
MIRMUnited States
30 filed reports · 397 financial concepts · 0 earnings calls · 0 media appearances
Filed reports
30 reports · Jun 2019 to Jun 2026Each report counts once it has at least one extracted financial fact. Also extracted from these reports: 2 guidance figures.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Quarterly · 10-QSEC EDGAR | 22 | 3,550 | Jun 2019 to Jun 2026 |
| Annual · 10-KSEC EDGAR | 7 | 2,711 | Dec 2019 to Dec 2025 |
| Current · 8-KSEC EDGAR | 1 | 2 | Jun 2026 |
Documents
| Period | Type | Period end | Published | Facts | Source |
|---|---|---|---|---|---|
| FY2026 Q2 | 10-Q | Jun 30, 2026 | Aug 5, 2026 | 437 | Open |
| FY2026 Q2 | 8-K | Jun 30, 2026 | Aug 5, 2026 | 2 | Open |
| FY2026 Q1 | 10-Q | Mar 31, 2026 | May 6, 2026 | 262 | Open |
| FY2025 | 10-K | Dec 31, 2025 | Feb 25, 2026 | 819 | Open |
| FY2025 Q3 | 10-Q | Sep 30, 2025 | Nov 4, 2025 | 263 | Open |
| FY2025 Q2 | 10-Q | Jun 30, 2025 | Aug 6, 2025 | 164 | Open |
| FY2025 Q1 | 10-Q | Mar 31, 2025 | May 7, 2025 | 163 | Open |
| FY2024 | 10-K | Dec 31, 2024 | Feb 26, 2025 | 442 | Open |
| FY2024 Q3 | 10-Q | Sep 30, 2024 | Nov 12, 2024 | 174 | Open |
| FY2024 Q2 | 10-Q | Jun 30, 2024 | Aug 7, 2024 | 160 | Open |
| FY2024 Q1 | 10-Q | Mar 31, 2024 | May 8, 2024 | 155 | Open |
| FY2023 | 10-K | Dec 31, 2023 | Mar 15, 2024 | 448 | Open |
Financial data
397 concepts · 6,263 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
Financial387 concepts · 6,000 facts · Jun 2018 to Jul 2026
- Corporate debt securities132 · Jun 2019 to Jun 2026
- Stockholders equity (US GAAP)41 · Jun 2018 to Jun 2026
- Cash cash equivalents restricted cash and restricted cash equivalents including disposal group and discontinued operations40 · Sep 2018 to Jun 2026
- Common stock par or stated value per share39 · Dec 2018 to Jun 2026
- Common stock shares authorized39 · Dec 2018 to Jun 2026
- Income tax expense benefit39 · Jun 2018 to Jun 2026
- Accounts payable current38 · Dec 2018 to Jun 2026
- Accrued clinical trials38 · Dec 2018 to Jun 2026
- Accrued professional fees current38 · Dec 2018 to Jun 2026
- Additional paid in capital common stock38 · Dec 2018 to Jun 2026
- Assets38 · Dec 2018 to Jun 2026
- Assets current38 · Dec 2018 to Jun 2026
- Cash and cash equivalents at carrying value38 · Dec 2018 to Jun 2026
- Common stock capital shares reserved for future issuance38 · Dec 2018 to Jun 2026
- Common stock shares issued38 · Dec 2018 to Jun 2026
- Common stock shares outstanding38 · Dec 2018 to Jun 2026
- Common stock value38 · Dec 2018 to Jun 2026
- Comprehensive income net of tax38 · Sep 2018 to Jun 2026
- Employee related liabilities current38 · Dec 2018 to Jun 2026
- Liabilities38 · Dec 2018 to Jun 2026
- Liabilities and stockholders equity38 · Dec 2018 to Jun 2026
- Liabilities current38 · Dec 2018 to Jun 2026
- Net income loss38 · Sep 2018 to Jun 2026
- Operating expenses (US GAAP)38 · Sep 2018 to Jun 2026
Product1 concepts · 146 facts · Dec 2020 to Jun 2026
- Revenue146 · Dec 2020 to Jun 2026
Segment8 concepts · 115 facts · Dec 2022 to Jun 2026
- Revenue37 · Dec 2022 to Jun 2026
- Cost of goods and service excluding depreciation depletion and amortization14 · Dec 2022 to Jun 2026
- Employee benefits and share based compensation14 · Dec 2022 to Jun 2026
- General and administrative expense (US GAAP)14 · Dec 2022 to Jun 2026
- Operating income loss14 · Dec 2022 to Jun 2026
- Reportable Segment14 · Dec 2022 to Jun 2026
- Acquired in-process research and development4 · Mar 2025 to Jun 2026
- Amortization of intangible assets4 · Mar 2025 to Jun 2026
Guidance1 concepts · 2 facts · Aug 2026
- Revenue Guidance2 · Aug 2026
Segments
261 factsFigures broken down by business line, region, product or another axis the company reports on.
Product or service6 members · 146 facts
- Product70 · Dec 2020 to Jun 2026
- Livmarli21 · Dec 2021 to Jun 2026
- Bile Acid Medicines19 · Dec 2021 to Jun 2026
- License16 · Dec 2020 to Dec 2023
- License And Other Revenue15 · Dec 2022 to Dec 2025
- License Revenue5 · Dec 2021 to Dec 2023
Statement business segments1 member · 115 facts
- Reportable115 · Dec 2022 to Jun 2026
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
- Earnings-release commentary104 claims from 10 reports · Sep 2024 to Jun 2026
- Management discussion (MD&A) commentary145 claims from 8 reports · Sep 2024 to Jun 2026
- Risk-factor changes26 claims from 1 reports · Dec 2025
- Risk factors150 risks from 2 annual reports · 2024 to 2025
Earnings calls
Transcripts with management claims and analyst questions, one per fiscal period.
No earnings-call transcripts for this company.
Executive media
Podcasts, interviews and conference appearances by the company's executives, with their claims.
No media appearances for this company.
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Oct 16, 2026) and refreshed every few hours.